TNFRSF9 and carcinoma: Importantly, we subsequently showed that a combination of anti-CD137/PD-1 mAbs with the anti-cancer drug cisplatin significantly prolongs life and is probably curative to 80% of mice with established ID8 carcinoma by a mechanism that involves functional CD8+ T cells and has tumor antigen specificity as well as immunological memory.